Verisign falls
Digest more
VeriSign is set to announce its earnings on July 24. In last five years, VRSN stock has displayed an equal division in one-day returns following earnings announcements.
BERKSHIRE Hathaway sold about one-third of its stake in VeriSign, an internet infrastructure and domain name registry company that Warren Buffett’s conglomerate has invested in since 2012, VeriSign said on Monday.
StockStory.org on MSN1h
Why VeriSign (VRSN) Shares Are Trading Lower TodayShares of domain name registry operator Verisign (NASDAQ:VRSN) fell 8.5% in the morning session after news that major shareholder Berkshire Hathaway sold a significant portion of its stake in the company at a discount.
VeriSign shares declined after the company announced an underwritten secondary offering of its common stock by affiliates of Berkshire Hathaway. The stock fell 7.5% to $283.01 in after-hours trading on Monday. Shares have risen 48% year to date through market close.
7h
InvestorsHub on MSNVeriSign shares drop after Berkshire Hathaway prices secondary offeringVeriSign, Inc. (NASDAQ:VRSN) saw its stock fall 6.5% in pre-market trading following Berkshire Hathaway’s announcement of a secondary offering of 4.3 million VeriSign shares priced at $285.00 each. The offering is priced at a notable discount to VeriSign’s previous closing price of $305.
Explore more
Berkshire Hathaway will sell about one-third of its more than $4 billion stake in VeriSign, an internet infrastructure and domain name registry company that Warren Buffett's conglomerate has invested in since 2012,
VeriSign shares dropped after the company released the pricing of its previously announced underwritten secondary offering of its common stock by affiliates of Berkshire Hathaway. Shares were down 7% at $284.72 on Tuesday. The stock has been down 1.6% this month.
10hon MSN
The Sage of Omaha's company will make over $1.2 billion from the sale, according to an announcement on Monday.
Revenue at SoFi jumps 44%, UnitedHealth restores financial guidance, and Sarepta soars after being notified by the FDA the company may lift its voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne muscular dystrophy.